MedTrace Logo

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

NCT05164536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-02-28

No results posted yet for this study

Summary

The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Amyvid

All participants will undergo a single β-amyloid PET scan with Amyvid.

Sponsors & Collaborators

  • Invicro

    lead OTHER

Principal Investigators

  • David Russell · Invicro

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-27
Primary Completion
2022-11-08
Completion
2022-11-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05164536 on ClinicalTrials.gov